Lilly investors got the jitters, saw better opportunities elsewhere, or decided to hold onto their chips. In the third ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

Results for its new CagriSema drug, while promising, fell below expectations, sending shares of the pharmaceutical giant down ...

Novo Nordisk (NVO) increased valuation gap with Eli Lilly (LLY) after its Phase 3 data for next-gen weight loss drug ...

Illustration: Elizabeth Smelov Novo Nordisk shares dived Friday after an experimental anti-obesity treatment missed ...

Novo Nordisk, Europe’s largest company by market value, faced a stock market bloodbath on Friday after disappointing results ...

Investors and analysts had eagerly awaited this data as a test of Novo’s case that it has a strong pipeline of drugs to ...

New clinical trial data from Novo Nordisk raise questions for the broad landscape of obesity drug development and the way ...

The competition between Eli Lilly and Novo Nordisk, makers of Zepbound and Wegovy, reflects the growing interest in the weight loss drug market. Currently, Novo Nordisk leads with Wegovy ...

In third place, for the first time, is Novo Nordisk’s major anti-obesity med Wegovy. Novo has been spending—and spending big on TV ads for the GLP-1 drug, but iSpot has been filing Wegovy’s ...

In the first head-to-head test, Eli Lilly's Zepbound obesity drug helped people lose significantly more weight than its main competitor, Novo Nordisk's Wegovy. People taking Zepbound lost 20.2% of ...